A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 98,700 shares of MCRB stock, worth $80,934. This represents 0.0% of its overall portfolio holdings.

Number of Shares
98,700
Previous 36,900 167.48%
Holding current value
$80,934
Previous $28,000 153.57%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.75 - $1.56 $2,547 - $5,299
3,397 Added 313.67%
4,480 $3,000
Q4 2023

Feb 14, 2024

SELL
$0.93 - $2.15 $173,713 - $401,596
-186,789 Reduced 99.42%
1,083 $1,000
Q3 2023

Nov 14, 2023

BUY
$2.33 - $5.07 $340,410 - $740,721
146,099 Added 349.75%
187,872 $447,000
Q2 2023

Aug 14, 2023

SELL
$4.67 - $6.55 $2.28 Million - $3.2 Million
-487,920 Reduced 92.11%
41,773 $200,000
Q1 2023

May 15, 2023

BUY
$4.95 - $6.09 $2.61 Million - $3.21 Million
527,064 Added 20048.08%
529,693 $3 Million
Q4 2022

Feb 14, 2023

SELL
$5.09 - $9.05 $157,581 - $280,178
-30,959 Reduced 92.17%
2,629 $14,000
Q3 2022

Nov 14, 2022

SELL
$3.5 - $7.2 $456,760 - $939,621
-130,503 Reduced 79.53%
33,588 $216,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $7.62 $196,792 - $555,391
-72,886 Reduced 30.76%
164,091 $563,000
Q1 2022

May 16, 2022

SELL
$6.3 - $8.84 $1 Million - $1.4 Million
-158,755 Reduced 40.12%
236,977 $1.69 Million
Q4 2021

Feb 14, 2022

BUY
$6.02 - $11.43 $1.81 Million - $3.44 Million
300,526 Added 315.66%
395,732 $3.3 Million
Q3 2021

Nov 15, 2021

SELL
$5.46 - $22.6 $1 Million - $4.16 Million
-184,057 Reduced 65.91%
95,206 $663,000
Q2 2021

Aug 16, 2021

SELL
$18.46 - $24.36 $1.12 Million - $1.48 Million
-60,939 Reduced 17.91%
279,263 $6.66 Million
Q1 2021

May 17, 2021

BUY
$17.66 - $28.92 $894,143 - $1.46 Million
50,631 Added 17.48%
340,202 $7.01 Million
Q4 2020

Feb 16, 2021

BUY
$23.25 - $37.73 $5.05 Million - $8.2 Million
217,253 Added 300.41%
289,571 $7.1 Million
Q3 2020

Nov 16, 2020

BUY
$3.74 - $28.74 $149,499 - $1.15 Million
39,973 Added 123.58%
72,318 $2.05 Million
Q2 2020

Aug 14, 2020

SELL
$3.04 - $6.2 $39,164 - $79,874
-12,883 Reduced 28.48%
32,345 $154,000
Q1 2020

May 15, 2020

SELL
$2.64 - $3.82 $9,292 - $13,446
-3,520 Reduced 7.22%
45,228 $161,000
Q4 2019

Feb 14, 2020

BUY
$2.99 - $4.42 $92,244 - $136,361
30,851 Added 172.38%
48,748 $168,000
Q3 2019

Nov 14, 2019

SELL
$2.29 - $4.16 $109,329 - $198,606
-47,742 Reduced 72.73%
17,897 $71,000
Q2 2019

Aug 14, 2019

BUY
$2.28 - $7.35 $113,500 - $365,890
49,781 Added 313.92%
65,639 $212,000
Q1 2019

May 15, 2019

SELL
$4.83 - $7.21 $137,997 - $205,996
-28,571 Reduced 64.31%
15,858 $0
Q4 2018

Feb 14, 2019

BUY
$4.52 - $8.88 $58,891 - $115,697
13,029 Added 41.49%
44,429 $200,000
Q3 2018

Nov 13, 2018

BUY
$7.33 - $9.23 $74,641 - $93,989
10,183 Added 47.99%
31,400 $0
Q2 2018

Aug 10, 2018

SELL
$6.91 - $9.55 $799,535 - $1.11 Million
-115,707 Reduced 84.5%
21,217 $0
Q1 2018

May 11, 2018

SELL
$7.34 - $11.16 $5,431 - $8,258
-740 Reduced 0.54%
136,924 $1.01 Million
Q4 2017

Feb 09, 2018

BUY
$9.15 - $12.64 $1.26 Million - $1.74 Million
137,664
137,664 $1.4 Million

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $102M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.